Clinical Trial Update: A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update examining the safety, tolerability, and immunogenicity of a fifth dose of Pfizer's 6-Valent OspA-based Lyme disease vaccine; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lyme Disease

Drugs mentioned

• 6-Valent OspA-Based Lyme Disease Vaccine

Snippet

Sponsor: Pfizer | Conditions: Lyme Disease | Phase 3 | Status: NOT_YET_RECRUITING